ArticleMedicine2025
Association between virus exposure and erectile dysfunction in US adults.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
This research aims to investigate the relationship between virus seropositivity and the occurrence of erectile dysfunction (ED). We obtained data from the U.S. Centers for Disease Control and Prevention's National health and nutrition examination survey regarding ED, hepatitis A, herpes simplex virus type 1, herpes simplex virus type 2, and cytomegalovirus, along with sociodemographic variables. We then evaluated the associations between ED and viral exposure using adjusted multivariable models. A total of 3184 participants were included in the subsequent analysis. In this study, males with ED were found to have lower levels of education, were married or living with partner, belonged to a lower socio-economic status, had a less physically active lifestyle, were smokers, and also had diabetes (all with a significance of P < .05). Our study investigating the relationship between Hepatitis A seropositivity and ED found that patients with Hepatitis A seropositivity had a higher likelihood of experiencing ED. This link remained statistically significant even when accounting for various other factors (odds ratio [OR] = 1.98; 95% confidence interval [CI] = 1.65-2.36; P < .0001). Additionally, we found that exposure to cytomegalovirus (CMV), determined by the presence of anti-CMV IgG antibodies, was also associated with ED (OR = 1.47; 95% CI = 1.14-2.25; P = .0329). This relationship remained significant after accounting for various covariates. In contrast, no associations were found between ED and seropositivity for herpes simplex virus type 1 (HSV-1) or type 2 (HSV-2) in the sample (all P values < 0.05). This study found that seropositivity for Hepatitis A or CMV is associated with ED.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.